We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis
Read MoreHide Full Article
PerkinElmer, Inc. recently launched a dry blood spot (DBS)-based test for SARS-CoV-2 IgG using its GSP/DELFIA platform. The platform enables processing of up to 5,000 samples per day. The finger-prick sample collection device facilitates both decentralized sample collection and high-throughput testing
Notably, the product is being commercially rolled out as a CE-IVD test and the company intends to apply for its FDA Emergency Use Authorization (EUA) soon.
This should boost the company’s Diagnostics segment.
More on the DBS Test
The DBS assay is operated on PerkinElmer’s GSP analyzer, which is a fully-automated and high-output system that enables large population testing. The GSP combined with the universal TRF (time resolved fluorescence) of the DELFIA platform is equipped to screen more than 30% of all newborn babies across 32 countries.
The traceable DBS workflow consists of five main components -- sample collection, punching, measurement on the GSP analyzer, reagents, and software, to identify anti-SARS-CoV-2 IgG antibodies. The SARS-CoV-2 IgG assay can also be run with serum or plasma samples via the company’s Victor2D platform.
DBS tests help curb costs and logistical obstacles related to collecting, transporting and processing venous blood for SARS-CoV-2 antibody testing.
Recent Developments
In June 2020, PerkinElmer’s EUROIMMUN attained FDA EUA for its EURORealTime SARS-CoV-2 assay. Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity tests are allowed to immediately begin utilizing this CE-marked RT-PCR test to diagnose SARS-CoV-2, the virus causing COVID-19.
In May, the company received EUA from the FDA for EUROIMMUN’s Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified under CLIA can start utilizing this ELISA for the detection of antibodies of the immunoglobulin class G immediately.
Market Prospects
Per a report published on Grand View Research, the global molecular diagnostics market was valued at $9.2 billion in 2019 and is expected to reach $18.2 billion by 2027, at a CAGR of 9%. Hence, the latest development has been a well-timed one for PerkinElmer.
Price Performance
Over the past three months, shares of the company have gained 27.9% compared with the industry’s growth of 21.4%.
Zacks Rank and Other Key Picks
PerkinElmer currently sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space are Laboratory Corporation of America Holdings (LH - Free Report) , Surmodics (SRDX - Free Report) and Quest Diagnostics (DGX - Free Report) .
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy).
Quest Diagnostics’ long-term earnings growth rate is estimated at 7.6%. It currently carries a Zacks Rank #1.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis
PerkinElmer, Inc. recently launched a dry blood spot (DBS)-based test for SARS-CoV-2 IgG using its GSP/DELFIA platform. The platform enables processing of up to 5,000 samples per day. The finger-prick sample collection device facilitates both decentralized sample collection and high-throughput testing
Notably, the product is being commercially rolled out as a CE-IVD test and the company intends to apply for its FDA Emergency Use Authorization (EUA) soon.
This should boost the company’s Diagnostics segment.
More on the DBS Test
The DBS assay is operated on PerkinElmer’s GSP analyzer, which is a fully-automated and high-output system that enables large population testing. The GSP combined with the universal TRF (time resolved fluorescence) of the DELFIA platform is equipped to screen more than 30% of all newborn babies across 32 countries.
The traceable DBS workflow consists of five main components -- sample collection, punching, measurement on the GSP analyzer, reagents, and software, to identify anti-SARS-CoV-2 IgG antibodies. The SARS-CoV-2 IgG assay can also be run with serum or plasma samples via the company’s Victor2D platform.
DBS tests help curb costs and logistical obstacles related to collecting, transporting and processing venous blood for SARS-CoV-2 antibody testing.
Recent Developments
In June 2020, PerkinElmer’s EUROIMMUN attained FDA EUA for its EURORealTime SARS-CoV-2 assay. Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity tests are allowed to immediately begin utilizing this CE-marked RT-PCR test to diagnose SARS-CoV-2, the virus causing COVID-19.
In May, the company received EUA from the FDA for EUROIMMUN’s Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified under CLIA can start utilizing this ELISA for the detection of antibodies of the immunoglobulin class G immediately.
Market Prospects
Per a report published on Grand View Research, the global molecular diagnostics market was valued at $9.2 billion in 2019 and is expected to reach $18.2 billion by 2027, at a CAGR of 9%. Hence, the latest development has been a well-timed one for PerkinElmer.
Price Performance
Over the past three months, shares of the company have gained 27.9% compared with the industry’s growth of 21.4%.
Zacks Rank and Other Key Picks
PerkinElmer currently sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space are Laboratory Corporation of America Holdings (LH - Free Report) , Surmodics (SRDX - Free Report) and Quest Diagnostics (DGX - Free Report) .
LabCorp’s long-term earnings growth rate is estimated at 6.1%. The company presently carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy).
Quest Diagnostics’ long-term earnings growth rate is estimated at 7.6%. It currently carries a Zacks Rank #1.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>